Navigation Links
MIV Therapeutics Announces Renowned Researcher to Detail Milestone,Pre-Clinical Results at Prominent International Conference EuroPCR,2007

ATLANTA--(BUSINESS WIRE)--May 22, 2007 - MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next generation biocompatible coatings and advanced drug delivery systems for Cardiovascular stents and other implantable medical devices, is pleased to announce that results from an animal trial comparing its proprietary polymer free Hydroxyapatite-coated drug-eluting cardiovascular stent to J&J's Cypher Stent will be presented at this weeks EuroPCR 2007 conference in Barcelona, Spain.

Dr Willem J. van der Giesen, MD, PhD from the Erasmus University Medical Center will make a presentation on next generation drug eluting stents, in which he will discuss the results of the 4 week porcine study, performed by the Department of Cardiology, Thoraxcenter, Erasmus University Medical Center in the Netherlands, an independent research organization.

The study indicated that three variations of MIVT's Hydroxyapatite-based Drug-Eluting stents were at least as effective as, and in some cases, better than one of the worlds leading drug-eluting cardiovascular stents produced by Johnson & Johnson (Cypher(TM)). These results provided the necessary data to advance the technology to human studies.

Hydroxyapatite, unlike polymer coatings, is naturally derived and found in such hard tissues and bioceramic materials as human bone and teeth. Research has indicated that MIVT's HAp coatings do not trigger the various adverse and inflammatory reactions that are often associated with implantation of polymer-coated stents and other foreign substances.

HAp coatings are also expected to reduce the risk of thrombogenic (blood clotting) events attributable in some instances to polymer-coated stents. Some of the most recent information presented at various conferences estimated that thrombogenicity was identified in at least 20,000 cases of implanted drug-eluting stents to-date, resulting in approximately 8,000
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
(Date:9/30/2014)... September 30, 2014 Dynamic health ... hampered growth in the Bread Production industry over ... consumers to moderate their consumption of a variety ... premium varieties shrunk the market for white loaf ... proactively responded by introducing more nutritious products to ...
(Date:9/30/2014)... research team has been awarded a three-year $1.7 ... (NIH) to develop new imaging technologies and data ... how large networks of neurons in the brain ... help researchers identify the precise interactions between millions ... and speaking, and alterations in these interactions that ...
(Date:9/30/2014)... 2014 The American Diabetes Association ... diabetics curb their sweet tooth, but the most recent ... September, suggests that zero-calorie sweeteners may actually be linked ... , The Weizmann Institute of Science in Israel ... to mice, the mice developed glucose intolerance. They then ...
(Date:9/30/2014)... Tampa, FL (PRWEB) September 30, 2014 ... doors to two new clinics in Nashville, Tennessee. RMS ... Sleep Apnea Institute, and the expansion of a new ... the introduction of the Sleep Apnea Institute to Nashville, ... that suffer from sleep apnea: both diagnosed and undiagnosed. ...
(Date:9/30/2014)... News) -- Medicare should cover low-dose computed tomography lung ... disease, a coalition of more than 60 patient and ... Lung Cancer Alliance, the Society of Thoracic Surgeons, the ... the American Society of Clinical Oncology, made its point ... for Medicare & Medicaid Services (CMS). Such screening ...
Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... Benedict XVI’s intention of soliciting a report on the acceptability ... //in exceptional cases, such as, in the event of either ... life within the precincts of marriage. ,Experts have commended ... issue such as this, while also agreeing that such an ...
... on its last lap of seeking enrollment from drug companies, and ... with three major insurance players. ,United Health Group seems to ... endorsers and a financial agreement with them to support the company. ... Medicare. ,80 companies have been in the fray with ...
... mother’s heart disease rather than the father’s tend to pose ... history of coronary disease//. ,The results of the ... American Journal of Preventive Medicine. This could help to better ... coronary problems as well as show early signs of the ...
... getting known for its severe dearth of general practitioners, further ... in the throes of a severe GP crisis. ,The ... the current trend of Doctors, gravitating to specialist sectors, which ... GP sector lean and totally understaffed. ,Dr Catherine ...
... been accused of the murder of three family members whose ... court appearance. // ,The victims were Marc Richardson, ... and a funeral visitation has been planned for them today ... Toussaint Church in Sudbury. ,The girl's boyfriend, an ...
... The World Health Organization WHO has recently released its ... // The United Nations health agency found that ... they are adequately nurtured and they claimed that the ... ,The W.H.O. says it now has scientific evidence ...
Cached Medicine News:Health News:Risk of Heart Disease Greater from Mom than Dad 2Health News:An International Growth Standard For Childs Releases By WHO 2
... 2 60-ms bursts of 50 Hz separated by .75 ... Tetanus: 50 Hz (50 pulses/s) or 100 Hz (100 ... Output Current: Adjustable from 0-70 mA , Stimulus ... Battery LED (green) indicates that the units on; it ...
Anesthesia Associates Nerve Stimulator Model AA 1050...
... newest peripheral nerve stimulator from B. Braun Medical. ... providing advanced digital technology. , ,Your ability ... allows the localization of practically all mixed nerves ... ,An additional optional component for the HNS11 is ...
... original MS-III design the new ... keypad and battery ... MS-IV peripheral nerve stimulator can ... in operating room, post anesthesia ...
Medicine Products: